Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766

  • 35 Accesses

  • 6 Citations

Abstract

The efficacy of the neurotrophic peptide ORG 2766 in diabetic patients with polyneuropathy was evaluated in a double-blind, placebo-controlled, multicentre trial. One hundred and twenty four patients were randomised in five groups to receive 0.1, 0.4, 2 or 5 mg ORG 2766 or placebo, once daily, administered subcutaneously 52 weeks. Thermal discrimination thresholds (TDT) and vibration perception thresholds (VPT), motor and sensory nerve conduction velocity, Hoffmann reflex, heart rate variation during deep breathing and heart rate response after standing up, neurological examination score and neuropathic symptom score were determined at baseline and after 17, 34 and 52 weeks of treatment. Of the nerve function indices studied, at week 52 the TDTwarmth of the hand in the ORG 2766 0.1, 0.4 and 5 mg groups and the TDTcold of the foot in the ORG 2766 0.1 and 0.4 mg groups significantly improved compared with placebo. Further significant improvement as compared with placebo was observed in the paraesthesia score at week 34 and week 52 in the ORG 2766 2 mg group. Only at week 34 had both the heartbeat variation during deep breathing and the VPT of the foot in the ORG 2766 0.1 mg group improved significantly, compared with placebo. No further statistically significant differences were observed at time for the other measures. No adverse reactions were observed. The only recorded drug-induced side effect was pain at the injection site. Taking all measures of efficacy into account, the statistically significant results observed did not show consistency within each measure. Therefore, it is concluded that ORG 2766, in contrast to earlier reports, is not effective in treating diabetic polyneuropathy.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Boulton AJM, Knight G, Drury J, Ward JD (1985) The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care 8:125–128

  2. 2.

    Boulton AJM, Levin S, Comstock J (1990) A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33:431–437

  3. 3.

    Bravenboer B, Dam PS van, Hop J, Steenhoven J van de, Erkelens DW (1992) Thermal threshold testing for the assessment of small fibre dysfunction: normal values and reproducibility. Diabet Med 9:546–549

  4. 4.

    Bravenboer B, Kappelle AC, Buren T van, Erkelens DW, Gispen WH (1992) ACTH(4–9) analogue Org 2766 improves existing neuropathy in the BB/Wor model (abstract). Diabetes 41:139

  5. 5.

    Bravenboer B, Kappelle AC, Buren T van, Erkelens DW, Gispen WH (1993) ACTH-analogue Org 2766 can ameliorate existing neuropathy in diabetic rats. Acta Diabetol 30:21–24

  6. 6.

    Bravenboer B, Hendrikse PH, Oey PL, Huffelen AC van, Groenhout C, Gispen WH, Erkelens DW (1994) Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4–9 analogue ORG 2766 in IDDM patients with neuropathy. Diabetologia 37:408–413

  7. 7.

    Brown MJ, Asbury AK (1984) Diabetic neuropathy. Ann Neurol 15:2–12

  8. 8.

    De Koning P, Gispen WH (1987) Org 2766 Improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 8:415–422

  9. 9.

    De Koning P, Brakkee JH, Gispen WH (1986) Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function: beneficial effects of melanocortins. J Neurol Sci 74:237–246

  10. 10.

    Delbridge L, Ctercteko G, Fowler C, Reeve TS, Le Quesne LP (1985) The aetiology of diabetic neuropahy ulceration of the foot. Br J Surg 72:1–6

  11. 11.

    De Neeling JND, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM (1994) Sensory thresholds in older adults: reproducibility and reference values. Muscle Nerve 17:454–461

  12. 12.

    Dyck PJ (1989) Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? Neurology 39:111–118

  13. 13.

    Edmonds ME (1986) The diabetic foot: pathophysiology and treatment. Clin Endocrinol Metab 15:889–916

  14. 14.

    Ewing DJ, Clarke BF (1982) Diagnosis and management of diabetic autonomic neuropathy. BMJ 285:916–918

  15. 15.

    Ewing DJ, Campbell IW, Murray A, Neilon JMM, Clarke BF (1978) Immediate heart-rate response to standing: simple test for autonomic neuropathy in diabetes. BMJ 1:145–147

  16. 16.

    Gerritsen van der Hoop R, Vecht CJ, Burg MEL van der, Elderson A, Boogerd W, Heimans JJ, Vries EP, Houwelingen JC van, Jennekens FGI, Gispen WH, Neijt JP (1990) Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 322:89–94

  17. 17.

    Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R (1993) Tolrestat for mild diabetic neuropathy. Ann Intern Med 118:7–11

  18. 18.

    Goldberg JM, Lindblom U (1979) Standardized method of determining vibratory perception thresholds for diagnosing and screening in neurological investigation. J Neurol Neurosurg Psychiatry 42:793–803

  19. 19.

    Harris M, Eastman R, Cowie C (1993) Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 16:1446–1452

  20. 20.

    Hendriksen PH, Oey PL, Wieneke GH, Bravenboer B, Banga JD (1992) Subclinical diabetic neuropathy: similarities between electrophysiological results of patients with Type 1 (insulindependent) and Type 2 (non-insulindependent) diabetes mellitus. Diabetologia 35:690–695

  21. 21.

    Jamal GA, Hansen S, Weir AI, Ballantyne JP (1985) An improved automated method for the measurement of thermal thresholds. 1. Normal subjects. J Neurol Neurosurg Psychiatry 48:354–360

  22. 22.

    Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, Henderson LM, Bissessar EA, Watkins PJ, Sampson M, Gale EAM, Scarpello J, Boddie HG, Hardy KJ, Thomas PK, Misra P, Halonen JP (1993) Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 16:8–15

  23. 23.

    Low PA (1987) Recent advances in the pathogenesis of diabetic polyneuropathy. Muscle Nerve 10:121–128

  24. 24.

    McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RE (1995) The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. Diabetes Care 18:216–219

  25. 25.

    Oh SJ (1984) Clinical electromyography: nerve conduction studies. University Park Press, Baltimore, pp 93–113

  26. 26.

    Reichard P, Nilsson BY, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309

  27. 27.

    Sundkvist G, Almer LO, Lilja B (1979) Respiratory influence on heart rate in diabetes mellitus. BMJ 1:924–925

  28. 28.

    Thomas PK, Scadding JW (1987) Treatment of pain in diabetic neuropathy. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr (eds) Diabetic neuropathy. Saunders, Philadelphia, pp 216–222

  29. 29.

    Tomlinson DR (1992) The pharmacology of diabetic neuropathy. Diabetes Metab Rev 8:67–84

  30. 30.

    Valk GD, Grootenhuis PA, Bouter LM, Bertelsmann FW (1994) Complaints of neuropathy related to the clinical and neurophysiological assessment of nerve function in patients with diabetes mellitus. Diabetes Res Clin Pract 26:29–34

  31. 31.

    Van der Zee CEEM, Gerritsen van der Hoop R, Gispen WH (1989) Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozotocininduced diabetic rats. Diabetes 38:225–230

  32. 32.

    Visser SL, Zonneveldt A, Rijke W de, Don JA, Martens EIF, Stam D (1983) Normal Hoffmann reflex latencies (HM interval) in relation to age and body length. Clin Neurol Neurosurg 85:85–91

  33. 33.

    Watkins PJ (1992) Clinical observations and experiments in diabetic neuropathy. Diabetologia 35:2–11

  34. 34.

    Winegrad AI (1987) Does a common mechanism induce the diverse complications of diabetes? Diabetes 36:396–406

  35. 35.

    Ziegler D, Mayer P, Rathmann W, Gries A (1991) One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Di abetes Res Clin Pract 14:63–74

Download references

Author information

Correspondence to Frederik W. Bertelsmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Valk, G.D., Kappelle, A.C., Tjon-A-Tsien, A.M.L. et al. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766. J Neurol 243, 257–263 (1996). https://doi.org/10.1007/BF00868523

Download citation

Key words

  • Neurotrophic peptide
  • ACTH(4–9) analogue
  • Diabetic polyneuropathy